Aurigen Medical was created by 2015/2016 BioInnovate fellows Dr John Thompson and Tony O’Halloran as a structural heart and EP company, developing the first entirely trans-septal implant to treat both the stroke and arrhythmia risk associated with persistent atrial fibrillation. Following investment from the Enterprise Ireland Commercialisation Fund, the company announced in May 2018 that it received €2.5million in the latest round of Horizon 2020 SME Instrument funding, placing first out of total of 1,280 entrants. AuriGen Medical will use its new funding to speed up commercialisation of its novel medical device.
- Established: 2017
- Funding: €2.95 million
- Status: Towards Commercialisation